2016
DOI: 10.1016/j.neuron.2016.01.016
|View full text |Cite
|
Sign up to set email alerts
|

Positive Allosteric Modulators of GluN2A-Containing NMDARs with Distinct Modes of Action and Impacts on Circuit Function

Abstract: To enhance physiological function of NMDA receptors (NMDARs), we identified positive allosteric modulators (PAMs) of NMDARs with selectivity for GluN2A subunit-containing receptors. X-ray crystallography revealed a binding site at the GluN1-GluN2A dimer interface of the extracellular ligand-binding domains (LBDs). Despite the similarity between the LBDs of NMDARs and AMPA receptors (AMPARs), GluN2A PAMs with good selectivity against AMPARs were identified. Potentiation was observed with recombinant triheterome… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

15
229
2
1

Year Published

2017
2017
2020
2020

Publication Types

Select...
7
1
1

Relationship

0
9

Authors

Journals

citations
Cited by 149 publications
(247 citation statements)
references
References 58 publications
(71 reference statements)
15
229
2
1
Order By: Relevance
“…Considerable progress has been made in the development of subunit-selective allosteric modulators (7)(8)(9)(10)(11)(12)(13), but the development of subtype-selective competitive NMDA receptor antagonists has been less successful. The competitive glutamate-site antagonist NVP-AAM077 (hereafter NVP) was originally reported to have 100-fold preference for GluN1/2A over GluN1/2B (14).…”
mentioning
confidence: 99%
“…Considerable progress has been made in the development of subunit-selective allosteric modulators (7)(8)(9)(10)(11)(12)(13), but the development of subtype-selective competitive NMDA receptor antagonists has been less successful. The competitive glutamate-site antagonist NVP-AAM077 (hereafter NVP) was originally reported to have 100-fold preference for GluN1/2A over GluN1/2B (14).…”
mentioning
confidence: 99%
“…There, synapses host an NGIC compliment kinetically suited to their input patterns (14) but are also capable of dynamically shifting between the priorities of integration and precision (8). Unsurprisingly then, influencing the deactivation kinetics of specific NGIC subtypes using allosteric modulators is a promising therapeutic objective (15)(16)(17).…”
mentioning
confidence: 99%
“…Elevated agonist concentrations can increase a modulator’s potency and conversely a PAM can increase agonist potency, as seen for SGE201 (Linsenbardt et al, 2014) and GNE-8324 (Hackos et al, 2016). In such cases, saturating agonist concentrations may mask potentiating activity if the primary PAM action is to increase agonist occupation.…”
Section: Discussionmentioning
confidence: 99%
“…In contrast to agents that potentiate NMDARs containing specific GluN2 subunits, e.g. pregnenalone sulphate (PS) (Horak et al, 2006), UBP710 -GluN2A/GluN2B; UBP512 - GluN2A (Costa et al, 2010); GNE-8324 - GluN2A (Hackos et al, 2016); CIQ – GluN2C/GluN2D (Mullasseril et al, 2010); PYD-106 – GluN2C (Khatri et al, 2014), the phenanthroic acid derivative UBP646 (Costa et al, 2010) and the cholesterol derivative SGE-201 (Paul et al, 2013) potentiate all four GluN1/GluN2 subtypes. Thus, in cases where it would be useful to augment global NMDAR function, agents with these properties may be beneficial.…”
Section: Introductionmentioning
confidence: 99%